Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Hospital Universitario San Ignacio
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05587088CT.gov Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Petiveria Alliacea Preparation (this asset) | Hospital Universitario San Ignacio | P1/2 | CC · 43 |
| Fludarabine | Sawa Ito, MD | P2/3 | BB |
| Cyclophosphamide | Sawa Ito, MD | P4 | BB |
| Cytarabine | Janssen Research & Development, LLC | P2/3 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
| Etoposide | SWOG Cancer Research Network | P2/3 | BB |
| Nivestim | Kura Oncology, Inc. | P2 | BB |
| Rituximab | SWOG Cancer Research Network | P2 | BB |
| Prednisone | SWOG Cancer Research Network | P2 | BB |
+42 more in the Acute Leukemia cohort
Other indications for Petiveria Alliacea Preparation
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Neoplasm | — | P1/2 | CCC · 48 |
| Pancreatic Neoplasm | — | P1/2 | CC · 45 |
| Colorectal Neoplasm | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Petiveria Alliacea Preparation in Acute Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/petiveria-alliacea-preparation-acute-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →